RE: The famous Resolutions 8, 9 and 311 Jun 2022 17:02
I agree with you. I have been watching almost all investment conference calls 4D management have been doing over last year or more. Their standard presentation theme is go through programmes, manufacturing facility and briefly catalysts. These were supposedly aimed at US based investors. In UK IG Duncan gives bit respect to Jeremy (Jeremy also puts slightly better questions) and on Proactive he comes like he was forcefully pulled to give interview. When you do presentation as a sales pitch, they must think from perspective of audience and what and why they will buy. While going through programmes, BoD should also explain plan, pathway to commercialization, how partners (Merck etc.) are involved in trials and what can be final result, market size and opportunities etc. They just put slides of preclinical/clinical results and remarks like we know what xyz strain does to improve conditions etc. They should of course explain their programmes but need also and more importantly explain how these will be commercialized. It is investor conference so they are interested in how can they get good return on their investment and in what timeframe, when you give presentation at ASCO etc. (medical conferences), you can be totally clinical data specific as that audience is different. After having so many conf. calls with HCW/Chardan etc. Duncan should understand this. Much more important is when you come on total retail shareholder specific channels like proactive, if you see Duncan's interview after Asthma phase 1 data, he was not bothered to enthuse viewers like he doesn't need retail investors. Whereas when CEO of companies like AVCT, AGL comes for interview they show much more enthusiasm and sell the dream and as a result those companies have much better retail support. Another thing is what was management thinking by not raising (probably was not possible) within their allowed limit of up to 40% after RCC trial result and then show funding weakness in annual result and notice of AGM and asking allowance of up to 100%. I am quite sure directors having good holding want this flexibility to raise at right time on Nasdaq at higher price but for that they will need to have some very exciting news/result or boom in biotech sector.